Navigation Links
An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists
Date:3/10/2010

WALTHAM, Mass., March 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an acute migraine therapy that is not contraindicated in patients with a history, symptoms or signs of vascular disease and also offers improved efficacy and fast-acting oral delivery would earn a 45 percent patient share in the treatment of migraine, according to surveyed U.S. neurologists. In Europe, such an agent would earn a 30 percent patient share, according to surveyed European neurologists.

The new report entitled Migraine (Acute): Neurologists' Expectations for a New Acute Therapy Extend Beyond Cardiovascular Safety finds that a new acute migraine drug that is free of the triptans' risk of cardiovascular side effects would be valued by clinicians and would enjoy a unique competitive advantage. However, the report shows that such an advantage would not be sufficient to fulfill surveyed neurologists' expectations for a new acute treatment.  

The report also finds Zogenix/Astellas Pharma/Desitin Pharmaceuticals' Sumavel DosePro (needle-free subcutaneous injectable sumatriptan) will earn Decision Resources' proprietary gold-standard status for migraine in 2013. Sumavel DosePro was launched in the U.S. in January 2010 and has been filed for approval in Europe. In 2009, Decision Resources' gold standard for migraine was Merck's Maxalt (rizatriptan oral tablet), owing in part to modest advantages in efficacy over other oral triptans. According to the report, Sumavel DosePro has competitive advantages in efficacy as compared to Maxalt on several of the end points that are most important to surveyed neurologists.  

"Among the current and emerging therapies profiled in the report, Sumavel DosePro benefits from fast-acting and robust efficacy at early time points," said Decision Resources Analyst Jon Searles. "Despite disadvantages in sustained pain freedom and certain side effects, Sumavel DosePro will become our clinical gold standard for migraine in 2013, although we forecast its use will be limited owing to its high cost, generics competition, reimbursement challenges and patient preference for oral pills."

About the Report

Migraine (Acute): Neurologists' Expectations for a New Acute Therapy Extend Beyond Cardiovascular Safety is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development. 

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

For more information, contact:

Decision Resources

Christopher Comfort

781-296-2597

ccomfort@dresources.com

SOURCE Decision Resources

Back to top

RELATED LINKS
http://www.decisionresources.com

'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
5. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
8. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
9. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
10. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
11. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... REDWOOD CITY, Calif. , March 28, 2017 ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that the European Medicines Agency ... (sufentanil sublingual tablet, 30 mcg) Marketing Authorisation Application ... review of the MAA is underway. The MAA ...
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, Inc., ... company, is pleased to announce that the Company ... of Panther Orthopedics, Inc., a San ... fixation solutions for orthopedic extremity applications.  ... expand rapidly, primarily due to procedure volume growth, ...
(Date:3/27/2017)... 2017 Therapix Biosciences Ltd. ... in the development of cannabinoid-based drugs, today announced ... the United States of 2,000,000 ... ordinary shares of the Company, at a price ... granted the underwriters a 45-day over-allotment option to ...
Breaking Medicine Technology:
(Date:3/28/2017)... CARTERSVILLE, Georgia (PRWEB) , ... March 28, 2017 ... ... analyst to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, ... been a leader in the real estate valuation industry for more than 40 ...
(Date:3/28/2017)... ... March 29, 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, one ... video series titled The Thyroid Secret. Dr. Wentz talked about journey and research recently ... fact that medication IS NOT the only solution to deal with thyroid disease. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... and by physicians, announced today the launch of a free, public-facing tool for ... Cost Analyzer (VCA) was developed to provide comparative information to patients, providers, insurers ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Usually, the impending ... daily wardrobe. However, for those self-conscious about a double chin, this means more anxiety ... ideal solution. , “For most people, a double chin is undesirable,” Dr. Goldman ...
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm , the ... headquarters to a new, more expansive office space in order to accommodate its ... a distressed office building in Wethersfield, Conn. located at 936 Silas Deane Highway ...
Breaking Medicine News(10 mins):